Phase II Randomized Study of Enzastaurin (LY317615) for Lung Cancer Prevention in Former Smokers

BACKGROUND: Chemoprevention for lung cancer with neutraceuticals or anti-inflammatory agents has had mixed clinical benefit. Novel targeted agents hold the promise of greater efficacy and selectivity. Here, we evaluated enzastaurin, a selective PKC-β inhibitor with antiproliferative and proapoptotic...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
मुख्य लेखकों: Gray, Jhanelle E., Altiok, Soner, Alexandrow, Mark G., Walsh, Frank W., Chen, Jian, Schell, Michael J., Tai, Datchen Fritz, Bepler, Gerold
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: 2012
विषय:
Article
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC3578040/
https://ncbi.nlm.nih.gov/pubmed/23065656
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.27836
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन